{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:42:32Z","timestamp":1780605752243,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,19]]},"DOI":"10.7759\/cureus.86333","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T07:44:26Z","timestamp":1750319066000},"source":"Crossref","is-referenced-by-count":1,"title":["Trastuzumab Emtansine (T-DM1)-Induced Porto-Sinusoidal Vascular Disorder: A Case Report"],"prefix":"10.7759","author":[{"given":"Catarina L","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari A","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al.. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021, 32:1475-95. 10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1021\/bc100498q","article-title":"Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism","volume":"22","author":"Sun X","year":"2011","unstructured":"Sun X, Widdison W, Mayo M, et al.. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem. 2011, 22:728-35. 10.1021\/bc100498q","journal-title":"Bioconjug Chem"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0369","article-title":"In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates","volume":"8","author":"Zheng B","year":"2009","unstructured":"Zheng B, Fuji RN, Elkins K, et al.. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009, 8:2937-46. 10.1158\/1535-7163.MCT-09-0369","journal-title":"Mol Cancer Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0580","article-title":"Ado-trastuzumab emtansine targets hepatocytes via human epidemal growth factor receptor 2 to induce hepatotoxicity","volume":"15","author":"Yan H","year":"2016","unstructured":"Yan H, Endo Y, Shen Y, et al.. Ado-trastuzumab emtansine targets hepatocytes via human epidemal growth factor receptor 2 to induce hepatotoxicity. Mol Cancer Ther. 2016, 15:480-90. 10.1158\/1535-7163.MCT-15-0580","journal-title":"Mol Cancer Ther"},{"key":"ref6","article-title":"","author":"European Medicines Agency","year":"2010","unstructured":"European Medicines Agency. Kadcyla: Drug Characteristics Summary. European Medicines Agency, Amsterdam, Netherlands; 2010. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kadcyla."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Di\u00e9ras V","year":"2014","unstructured":"Di\u00e9ras V, Harbeck N, Budd GT, et al.. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014, 32:2750-7. 10.1200\/JCO.2013.54.4999","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"De Gottardi A","year":"2019","unstructured":"De Gottardi A, Rautou PE, Schouten J, et al.. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019, 4:399-411. 10.1016\/S2468-1253(19)30047-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8543","article-title":"Nodular regenerative hyperplasia after treatment with trastuzumab emtansine","volume":"34","author":"Force J","year":"2016","unstructured":"Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, Vuppalanchi R. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol. 2016, 34:e9-12. 10.1200\/JCO.2013.49.8543","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrc.2015.11.008","article-title":"Trastuzumab emtansine associated nodular regenerative hyperplasia: a case report and review of literature","volume":"5","author":"Prochaska LH","year":"2016","unstructured":"Prochaska LH, Damjanov I, Ash RM, et al.. Trastuzumab emtansine associated nodular regenerative hyperplasia: a case report and review of literature. Cancer Treat Commun. 2016, 5:26-30. 10.1016\/j.ctrc.2015.11.008","journal-title":"Cancer Treat Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.7207","article-title":"Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?","volume":"17","author":"Lepelley M","year":"2018","unstructured":"Lepelley M, Allouchery M, Long J, et al.. Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?. Ann Hepatol. 2018, 17:1067-71. 10.5604\/01.3001.0012.7207","journal-title":"Ann Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220910252","article-title":"Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report","volume":"26","author":"Hassan C","year":"2020","unstructured":"Hassan C, Correal F, V\u00e9zina G, Yelle L, Adam JP. Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report. J Oncol Pharm Pract. 2020, 26:1780-4. 10.1177\/1078155220910252","journal-title":"J Oncol Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-019-00392-4","article-title":"Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer","volume":"9","author":"Fujii Y","year":"2020","unstructured":"Fujii Y, Doi M, Tsukiyama N, et al.. Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer. Int Cancer Conf J. 2020, 9:18-23. 10.1007\/s13691-019-00392-4","journal-title":"Int Cancer Conf J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000521933","article-title":"Trastuzumab emtansine-induced nodular regenerative hyperplasia: is dose reduction enough as a preventable measure?","volume":"40","author":"Garrido I","year":"2022","unstructured":"Garrido I, Magalh\u00e3es A, Lopes J, Macedo G. Trastuzumab emtansine-induced nodular regenerative hyperplasia: is dose reduction enough as a preventable measure?. Dig Dis. 2022, 40:787-92. 10.1159\/000521933","journal-title":"Dig Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220536","article-title":"Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT","volume":"305","author":"Choi SJ","year":"2022","unstructured":"Choi SJ, Lee SS, Jung KH, et al.. Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT. Radiology. 2022, 305:606-13. 10.1148\/radiol.220536","journal-title":"Radiology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356011-trastuzumab-emtansine-t-dm1-induced-porto-sinusoidal-vascular-disorder-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T07:44:26Z","timestamp":1750319066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356011-trastuzumab-emtansine-t-dm1-induced-porto-sinusoidal-vascular-disorder-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.86333","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}